Medication Review: What Is the Safety Profile of Guselkumab in PsO and PsA? b6032

Cassie Dolecki, PharmD, BS, Clinical Pharmacy Specialist in Rheumatology at Allegheny Health Network in Pittsburgh, PA, as she reviews the comprehensive safety data of Guselkumab (Tremfya) in the management of psoriatic arthritis (PsA) and psoriasis. The Discover-2 trial provides critical insights into the safety of Guselkumab compared to placebo in biologic-naïve PsA patients, highlighting infection rates and adverse events. Long-term safety data spanning over 11,000 patient-years across multiple phase 2 and phase 3 trials reinforce the consistency of Guselkumab’s safety profile across diverse patient populations. This discussion breaks down key findings on the incidence of serious infections, adverse events, and overall treatment tolerability, addressing critical questions about Guselkumab’s suitability as a long-term therapeutic option for psoriatic disease. For more expert insights on biologics, psoriatic disease management, and the latest in rheumatology research, visit RhAPP.org or explore the RhAPP ACE App. 5g4x3d